Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength

Vertex Pharmaceuticals raised its full-year sales forecast on Tuesday, banking on strong demand for its cystic fibrosis (CF) treatment.

The company now sees full-year sales from its CF treatments to be between $9.7 billion and $9.8 billion, from a prior forecast of $9.55 billion to $9.7 billion. This compares with $9.75 billion as estimated by analysts.